Page last updated: 2024-11-02

oxidopamine and Affective Disorders

oxidopamine has been researched along with Affective Disorders in 4 studies

Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).

Research Excerpts

ExcerptRelevanceReference
"Parkinson's disease is a neurodegenerative disease characterized by progressive dopaminergic neuronal loss."1.72Pharmacological Rescue with SR8278, a Circadian Nuclear Receptor REV-ERBα Antagonist as a Therapy for Mood Disorders in Parkinson's Disease. ( Choe, HK; Choe, Y; Choi, JW; Choi, M; Jang, S; Kim, D; Kim, J; Kim, K; Moon, C; Park, I; Park, SH; Sun, W, 2022)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Kim, J1
Park, I1
Jang, S1
Choi, M1
Kim, D1
Sun, W1
Choe, Y1
Choi, JW1
Moon, C1
Park, SH1
Choe, HK1
Kim, K1
Carvalho, MM1
Campos, FL1
Coimbra, B1
Pêgo, JM1
Rodrigues, C1
Lima, R1
Rodrigues, AJ1
Sousa, N1
Salgado, AJ1
Petri, D1
de Souza Silva, MA1
Chao, OY1
Schnitzler, A1
Huston, JP1
Singh, S1
Mishra, A1
Srivastava, N1
Shukla, S1

Other Studies

4 other studies available for oxidopamine and Affective Disorders

ArticleYear
Pharmacological Rescue with SR8278, a Circadian Nuclear Receptor REV-ERBα Antagonist as a Therapy for Mood Disorders in Parkinson's Disease.
    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2022, Volume: 19, Issue:2

    Topics: Animals; Humans; Isoquinolines; Mice; Mood Disorders; Neurodegenerative Diseases; Nuclear Receptor S

2022
Behavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits.
    Molecular neurodegeneration, 2013, Apr-26, Volume: 8

    Topics: Adrenergic Agents; Animals; Antidepressive Agents; Antiparkinson Agents; Behavior, Animal; Bupropion

2013
Serotonergic interaction between medial prefrontal cortex and mesotelencephalic DA system underlies cognitive and affective deficits in hemiparkinsonian rats.
    Neuroscience, 2015, Oct-29, Volume: 307

    Topics: Adrenergic Agents; Animals; Cognition Disorders; Disease Models, Animal; Excitatory Amino Acid Agoni

2015
MK-801 (Dizocilpine) Regulates Multiple Steps of Adult Hippocampal Neurogenesis and Alters Psychological Symptoms via Wnt/β-Catenin Signaling in Parkinsonian Rats.
    ACS chemical neuroscience, 2017, 03-15, Volume: 8, Issue:3

    Topics: Adaptation, Ocular; Animals; beta Catenin; Cell Proliferation; Disease Models, Animal; Dizocilpine M

2017